Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 1.00 |
| ▸ | EP300 | Q09472 | 3/20 | 1.00 |
| ▸ | KAT5 | Q92993 | 3/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 2/20 | 1.00 |
| ▸ | F7 | P08709 | 3/20 | 0.77 |
| ▸ | F3 | P13726 | 3/20 | 0.77 |
| ▸ | BID | P55957 | 7/20 | 0.73 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.73 |
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.73 |
| ▸ | BAK1 | Q16611 | 6/20 | 0.73 |
| ▸ | MMP2 | P08253 | 2/20 | 0.73 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | ECE1 | P42892 | 1/20 | 0.73 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.73 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.73 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anacardic Acid SCHEMBL32675978 | 1.00 | KAT8 (1.00) | KAT8EP300KAT5KAT2BF7 | |
| Anacardic Acid SCHEMBL21705058 | 1.00 | KAT8 (1.00) | KAT8EP300KAT5KAT2BF7 | |
| Anacardic Acid SCHEMBL154720 | 1.00 | KAT8 (1.00) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL4146215 | 0.87 | F7 (0.90) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL21926857 | 0.87 | F7 (0.90) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL5375284 | 0.87 | F7 (1.00) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL21705057 | 0.87 | F7 (0.90) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL154719 | 0.87 | F7 (0.90) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL5375286 | 0.87 | F7 (1.00) | KAT8EP300KAT5KAT2BF7 | |
| SCHEMBL5375291 | 0.87 | F7 (1.00) | KAT8EP300KAT5KAT2BF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000821-A1 | METHODS FOR INHIBITING ALPHA-V BETA-3 EXPRESSION ON CANCER STEM CELLS AND INHIBITING PROGRESSION TO A CANCER STEM CELL PHENOTYPE | UNIV CALIFORNIA (US) | 2018-01-04 | — | — | US | claimed |
| JP-5255063-A | — | — | None | — | — | JP | disclosed |
| JP-2255609-A | — | — | None | — | — | JP | disclosed |
| JP-6092837-A | — | — | None | — | — | JP | disclosed |
| US-11179306-B2 | Use of salicylic acid derivatives as prodesquamating active agent | L'OREAL (FR) | 2021-11-23 | — | — | US | disclosed |
| US-11052089-B2 | Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3068366-B1 | USE AS A DEODORANT AGENT OF A SALIFIED SALICYLIC ACID DERIVATIVE, ALONE OR IN A MIXTURE | OREAL (FR) | 2020-07-15 | — | — | EP | disclosed |
| EP-3068366-B1 | USE AS A DEODORANT AGENT OF A SALIFIED SALICYLIC ACID DERIVATIVE, ALONE OR IN A MIXTURE | OREAL (FR) | 2020-07-15 | — | — | EP | disclosed |
| EP-3212157-B1 | USE OF LIPOPHILIC SALICYLIC ACID DERIVATIVES | OREAL (FR) | 2019-04-10 | — | — | EP | disclosed |
| EP-3212157-B1 | USE OF LIPOPHILIC SALICYLIC ACID DERIVATIVES | OREAL (FR) | 2019-04-10 | — | — | EP | disclosed |
| US-20060216252-A1 | Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-09-28 | — | — | US | disclosed |
| EP-1648400-A1 | USE OF HALOGENATED HYDROXYDIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF THE SKIN | Ciba SC Holding AG (CH) | 2006-04-26 | — | — | EP | disclosed |
| US-20050058610-A1 | Cosmetic mixtures containing ultraviolet radiation absorber and decoloring agents | CIBA SPECIALTY CHEMICALS CORP. | 2005-03-17 | — | — | US | disclosed |
| WO-2005013931-A1 | USE OF HALOGENATED HYDROXYDIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF THE SKIN | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1432400-A1 | USE OF GUAIOL FOR TREATING THE SKIN | Ciba SC Holding AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003024417-A1 | USE OF GUAIOL FOR TREATING THE SKIN | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-03-27 | — | — | WO | disclosed |
| JP-H0692837-A | COSMETIC | TOHOKU KAKO KK | 1994-04-05 | — | — | JP | disclosed |
| JP-H05255063-A | EXTERNAL PREPARATION FOR SKIN | SHISEIDO CO LTD | 1993-10-05 | — | — | JP | disclosed |
| US-5202355-A | Administering for diabetic neuropathy | TAKASAGO INSTITUTE FOR INTERDISCIPLINARY SCIENCE INC. (US) | 1993-04-13 | — | — | US | disclosed |
| JP-H02255609-A | ANTIMICROBIAL AGENT COMPOSITION FOR ORAL CAVITY | SUNSTAR INC | 1990-10-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058610-A1 | Cosmetic mixtures containing ultraviolet radiation absorber and decoloring agents | TYR, MC1R, UNG | KAT8 2336/4885EP300 2056/4885KAT5 2909/4885 |
| US-11179306-B2 | Use of salicylic acid derivatives as prodesquamating active agent | HRH1, SUCNR1, PTGS1 | KAT8 2592/4885EP300 809/4885KAT5 1871/4885 |
| US-20060216252-A1 | Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin | MC1R, TYR, MC3R | KAT8 1170/4885EP300 343/4885KAT5 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.